Herriot Tabuteau - Axsome Therapeutics Chairman of the Board, CEO
| AXSM Stock | USD 74.89 1.13 1.53% |
Chairman
Dr. Herriot Tabuteau, M.D. Chief Executive Officer, President, Chairman of the Board of the Company. Dr. Tabuteau has served as our founder, Chief Executive Officer, and Chairman of our board of directors since our founding in January 2012. He is also the founder of Antecip Capital LLC, one of our principal stockholders, for which Dr. Tabuteau was the managing member since 2003. Dr. Tabuteau is also the managing member of Antecip Bioventures II LLC. Prior to founding our company, Dr. Tabuteau was a Senior Analyst and Partner at HealthcoS.A.C. Capital where he was responsible for the biotechnology, genomics, and instrumentation portfolios. Previously, Dr. Tabuteau was the healthcare analyst at Kingdon Capital. Prior to that position, Dr. Tabuteau was a Senior Research Analyst at Banc of America Securities covering the hospital supplies sector. Prior to Banc of America, Dr. Tabuteau was part of the healthcare investment banking group at Goldman Sachs since 2018.
| Age | 48 |
| Tenure | 6 years |
| Address | One World Trade Center, New York, NY, United States, 10007 |
| Phone | 212 332 3241 |
| Web | https://www.axsome.com |
Axsome Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2486) % which means that it has lost $0.2486 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5921) %, meaning that it created substantial loss on money invested by shareholders. Axsome Therapeutics' management efficiency ratios could be used to measure how well Axsome Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 2nd of May 2024, Return On Tangible Assets is likely to drop to -0.48. In addition to that, Return On Capital Employed is likely to drop to -0.43. At this time, Axsome Therapeutics' Other Assets are very stable compared to the past year. As of the 2nd of May 2024, Intangibles To Total Assets is likely to grow to 0.18, while Return On Tangible Assets are likely to drop (0.48).Similar Executives
| Found 6 records | CHAIRMAN Age | ||
| Robert Ready | LSI Industries | 73 | |
| Christopher Wilson | Invesco Trust For | 64 | |
| Kenneth Frazier | Merck Company | 67 | |
| Bruce Crockett | Invesco Trust For | 76 | |
| Robert JD | Merck Company | 57 | |
| Martin Flanagan | Invesco Trust For | 60 | |
Management Performance
| Return On Equity | -1.59 | ||||
| Return On Asset | -0.25 |
Axsome Therapeutics Leadership Team
Elected by the shareholders, the Axsome Therapeutics' board of directors comprises two types of representatives: Axsome Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Axsome. The board's role is to monitor Axsome Therapeutics' management team and ensure that shareholders' interests are well served. Axsome Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Axsome Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Constance Ames, VP of Fin. | ||
| Herriot Tabuteau, Chairman of the Board, CEO | ||
| Joseph DebrahAffu, Director of Finance, Interim Principal Accounting Officer | ||
| John Golubieski, CFO | ||
| Mark Saad, Independent Director | ||
| Lori MBA, Executive Development | ||
| Hunter Esq, General Secretary | ||
| Cedric OGorman, Senior Vice President- Clinical Development and Medical Affairs | ||
| Roger Jeffs, Independent Director | ||
| Robert Niecestro, Head of Regulatory Affairs and VP | ||
| Herriot MD, Founder, Chairman and CEO | ||
| Amanda PharmD, Senior Development | ||
| Randall MD, Chief Medical Officer | ||
| Mark Coleman, Independent Director | ||
| Myrtle Potter, Independent Director | ||
| Mark Jacobson, Senior Director - Operations | ||
| Mark MA, VP of Operations | ||
| Kevin PharmD, Ex Strategy | ||
| Randall Kaye, Chief Medical Officer | ||
| Nick Pizzie, CFO | ||
| MB CPA, Director Finance |
Axsome Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Axsome Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.59 | ||||
| Return On Asset | -0.25 | ||||
| Profit Margin | (0.88) % | ||||
| Operating Margin | (0.78) % | ||||
| Current Valuation | 3.29 B | ||||
| Shares Outstanding | 47.49 M | ||||
| Shares Owned By Insiders | 17.04 % | ||||
| Shares Owned By Institutions | 83.45 % | ||||
| Number Of Shares Shorted | 7.75 M | ||||
| Price To Earning | (3.34) X |
Axsome Therapeutics Investors Sentiment
The influence of Axsome Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Axsome. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Axsome Therapeutics' public news can be used to forecast risks associated with an investment in Axsome. The trend in average sentiment can be used to explain how an investor holding Axsome can time the market purely based on public headlines and social activities around Axsome Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Axsome Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Axsome Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Axsome Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Axsome Therapeutics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Axsome Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Axsome Therapeutics' short interest history, or implied volatility extrapolated from Axsome Therapeutics options trading.
Pair Trading with Axsome Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Axsome Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Axsome Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Axsome Stock
| 0.82 | MPW | Medical Properties Trust Aggressive Push | PairCorr |
| 0.67 | GCTK | GlucoTrack | PairCorr |
| 0.64 | AEZS | Aeterna Zentaris Financial Report 14th of May 2024 | PairCorr |
| 0.62 | LMAT | LeMaitre Vascular Financial Report 7th of May 2024 | PairCorr |
The ability to find closely correlated positions to Axsome Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Axsome Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Axsome Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Axsome Therapeutics to buy it.
The correlation of Axsome Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Axsome Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Axsome Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Axsome Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for Axsome Stock analysis
When running Axsome Therapeutics' price analysis, check to measure Axsome Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Axsome Therapeutics is operating at the current time. Most of Axsome Therapeutics' value examination focuses on studying past and present price action to predict the probability of Axsome Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Axsome Therapeutics' price. Additionally, you may evaluate how the addition of Axsome Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Global Correlations Find global opportunities by holding instruments from different markets |
Is Axsome Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.27) | Revenue Per Share 5.957 | Quarterly Revenue Growth 1.935 | Return On Assets (0.25) | Return On Equity (1.59) |
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.